Flucomap Tablet 150mg (Fluconazole)

Adult dose

The route of administration should be determined according to the patient's clinical condition. Because absorption of oral formulations is rapid and nearly complete, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. ○ Adults 1. Vaginal candidiasis: Administer a single 150 mg oral dose of fluconazole 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this medicine is 400 mg as a single dose on the first day, followed by 200 mg once daily from the next day; the dose may be increased to 400 mg once daily according to patient response. The duration of treatment is determined according to clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this medicine is 400 mg as a single dose on the first day, followed by 200-400 mg once daily from the next day. The duration of treatment is determined by clinical and mycological response, but treatment should usually continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg of this medicine once daily indefinitely after the patient has completed all initial treatment. 5. Prevention of fungal infections in immunocompromised patients at risk due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this medicine once daily according to the patient's risk of fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as those undergoing bone marrow transplantation who are expected to have severe or prolonged neutropenia. In these patients, administer 400 mg starting 5-6 days before the expected onset of neutropenia and continue administering 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or more. 6. For onychomycosis, administer 150 mg once weekly until the fingernail or toenail has regrown (until a new, uninfected nail has grown). It usually takes 3-6 months for a new fingernail to grow and 6-12 months for a new toenail to grow; growth rate may vary among individuals and by age. In some cases, the fingernails or toenails may remain damaged after successful long-term treatment. For dermatophyte infections of the skin, including athlete's foot (tinea pedis), tinea corporis, jock itch (tinea cruris), and cutaneous candidiasis: The usual dose of this medicine is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, athlete's foot may require treatment for 6 weeks depending on the course of the disease. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. ○ Elderly patients If renal function is normal, the usual adult dose is administered. If renal impairment is present (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. ○ Patients with renal impairment This medicine is excreted mainly in the urine unchanged. No dose adjustment is required for a single dose, but when multiple doses are required, administer the usual dose only on the first day and adjust the dose from the next day as follows. Creatinine clearance (mL/min) / Recommended dose > 50 / 100 % of the usual dose ≤50 (not on dialysis) / 50% of the usual dose Patients on hemodialysis / 100% of the usual dose after each hemodialysis session Patients on hemodialysis should receive 100% of the usual dose after each hemodialysis session. On non-dialysis days, administer a reduced dose according to creatinine clearance.

This medicine is an azole antifungal agent used for the treatment of fungal infections. This medication should not be administered to certain patients. For example, individuals with allergies to this drug or similar medications, pregnant or breastfeeding women, and patients taking certain heart medications or other drugs should not use this medication. Moreover, it should also be avoided in patients with certain genetic metabolic disorders such as lactose intolerance. Caution is required when administering this drug to patients with poor kidney or liver function, or those with heart disease or at risk for arrhythmias. Especially, this drug can affect heart rhythm, and side effects such as QT interval prolongation may occur; thus, cardiac status should be closely monitored. This medication can interact with several other drugs, so if you are taking other medications, you must inform your doctor or pharmacist, as dosage adjustments or monitoring may be necessary. This medication should be avoided during pregnancy, and fertile women should ensure effective contraception during and for some time after taking this medication. Breastfeeding women are also advised against using this medication. In children, especially infants younger than 6 months, safety has not been established, and caution is required. This medication may occasionally cause side effects such as headache, dizziness, gastrointestinal disturbances, skin rashes, among others, and rarely can lead to serious liver damage or blood abnormalities; therefore, if any unusual symptoms occur, immediate consultation with a medical professional is necessary. While driving or operating machinery, caution is needed as dizziness or seizures may occur. In case of overdose, psychiatric symptoms may be observed, and immediate medical treatment is required.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, taste disturbance, tremors, vertigo, Torsade de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, ALT increase, AST increase, increase in serum alkaline phosphatase, cholestasis, jaundice, bilirubin increase, hepatotoxicity, liver failure, hepatocyte necrosis, hepatitis, hepatocyte damage, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized pustular exanthema, exfoliative dermatitis, facial edema, hair loss, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, lethargy, weakness, fever, adrenal insufficiency, hallucinations, paranoid behavior

This medication may be susceptible to air and moisture, so it should be stored in a tightly sealed container. Additionally, avoid extremely hot or cold places and store it at normal room temperatures between 1 degree to 30 degrees Celsius.

Appearance

Pink oval tablet

Package unit

30 tablets/bottle